Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

R&D Investments, Pending Approvals, Acquisitions - Research Report on Optimer, Zogenix, Cubist, Merck and Questcor



R&D Investments, Pending Approvals, Acquisitions - Research Report on Optimer,
                     Zogenix, Cubist, Merck and Questcor

PR Newswire

NEW YORK, March 4, 2013

NEW YORK, March 4, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Optimer
Pharmaceuticals, Inc. (NASDAQ: OPTR), Zogenix, Inc. (NASDAQ: ZGNX), Cubist
Pharmaceuticals Inc (NASDAQ: CBST), Merck & Co., Inc. (NYSE: MRK) and Questcor
Pharmaceuticals, Inc. (NYSE: QCOR). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Optimer Pharmaceuticals, Inc. Research Report

Optimer shares rallied 13 percent following news that one of its "strategic
alternatives to maximize shareholder value" was to consider a possible sale.
The company's CEO Pedro Lichtinger will also resign and will be replaced on an
interim basis by former Pfizer Inc. CEO Henry A. McKinnell Jr. According to
Brian Skorney, an analyst for Robert W. Baird & Co., the company may be a
target for Pfizer or Johnson & Johnson. Furthermore, data compiled by
Bloomberg states that the company's revenue is projected to more than double
to $310 million by the end of 2017 from 2011. Fourth quarter earnings were 2
cents per share against an estimate of a 55 cent loss. With a change in
leadership and a possible sale, many analysts and investors are optimistic
about Optimer's future. The company's full report will The Full Research
Report on Optimer Pharmaceuticals, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.investors-alliance.com/r/full_research_report/757e_OPTR]

--

Zogenix, Inc. Research Report

Zogenix announced that the FDA has delayed approval for its Zohydro drug, a
long-acting version of the painkiller hydrocone. The FDA did not comment the
cause of the delay but stated that it would most likely be brief and may last
only for several weeks. Many remain optimistic that the FDA will approve the
drug, including Wells Fargo analyst Michael Tong. He comments, "We continue to
believe the odds for eventual approval are high. We speculate FDA is dealing
with issues of access and potential misuse." If approved, the drug will be the
first pure hydrocone medication in the United States, showing the potential of
this drug to generate returns for the company. The Full Research Report on
Zogenix, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/d33e_ZGNX]

--

Cubist Pharmaceuticals Inc Research Report

Cubist announced that it has entered into an option agreement with Adynxx in
which Cubist will have exclusive right to acquire Adynxx following the data
readout of Adynxx's Phase II trial for AYX1. Cubist is impressed with the
Phase I results and believes that the drug may be a new therapy for
post-surgical and chronic pain. Cubist will pay Adynxx to secure exclusive
rights to acquire the company with cash on hand, and additional payments will
be made to Adynxx shareholders if Cubist chooses to exercise its right to
acquire Adynxx.  This is one of Cubist's strategic efforts to strengthen its
pipeline. The Full Research Report on Cubist Pharmaceuticals Inc - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/0f29_CBST]

--

Merck & Co., Inc. Research Report

To strengthen its pipeline, Merck has entered into a biosimilars development
project and commercialization agreement with Samsung Bioepis Co., Ltd.
Biosimilars, or generic biologics, are drugs with active substances made from
living organisms. With their combined resources, the two companies aim to
promote public access to biosimilars. Furthermore, Merck presented new data
regarding its allergic rhinitis treatment. Developing its pipeline allows the
company to assure long-term growth and continue returning healthy dividends to
investors. Its most recent dividend was announced at 43 cents per share,
payable April 5, 2013. The Full Research Report on Merck & Co., Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/d004_MRK]

--

Questcor Pharmaceuticals, Inc. Research Report

Questcor Pharmaceuticals reported earnings that beat estimates, with adjusted
earnings per share of $1.09, up 132 percent from the same quarter a year ago.
The company's Acthar drug was the main driver for growth. Acthar sales were up
94 percent compared to 2011. In the coming year, Questcor intends to continue
investing in R&D programs and increase manufacturing capabilities. The company
is presently working on approximately 35 research projects, including some
Phase 4 projects. Lastly, the company has been repurchasing shares in order to
provide higher returns to investors. The Full Research Report on Questcor
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/21da_QCOR]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Patricia Byers
Email: press@Investors-Alliance.com
Main: +1-480-745-7826

SOURCE Investors-Alliance
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement